Friday, February 24, 2012

Multinationals driving Japan Pharma Growth

Highlights of Japan Pharma Ethical Drug Industry in 2011
  • Total Sales of ethical drugs in 2011 - ¥9.481578 trillion (NHI Price)
  • Year over Year growth of Ethical drug market :  + 6.9%
  • Sales of the HP Market (>100 beds) : ¥3.701742 trillion
  • Sales of the GP Market (< 100 beds) :  ¥2.294007 trillion
  • Sales of the dispensing Pharma market - ¥3.485830 trillion
  • Growth of the HP Market (>100 beds) :  6%
  • Growth of the GP Market (< 100 beds) : 6.6%
  • Growth of the Dispensing Pharma Market - 8.0%
  • Largest promotion company in Japan - Pfizer ( ¥576b +10.7%)
  • Second Largest promotion company in Japan - Takeda ( ¥559b +4.2%)
  • Third Largest promotion company in Japan - Daiichi Snakyo ( ¥480b +2.2% )
  • Third Largest promotion company in Japan - Mitsubishi Tanabe( ¥404b  +3.0%)
  • MSD jumped from eighth to fifth with sales of  ¥399.794 billion growign by +15.9%)
    GlaxoSmithKline (GSK) moved up from 12th to ninth (¥319.785 billion; +29.2%)
    Sanofi-aventis (¥315.350 billion; +10.6%; 10th),
    Nippon Boehringer Ingelheim (¥201.761 billion; +14.9%; 16th),
    Eli Lilly Japan (¥166.967 billion; +21.6%; 19th) also showed double-digit growth.

    Among Japanese companies, Kyowa Hakko Kirin (¥220.859 billion; +10.3%; 14th) and Ono Pharmaceutical (¥163.649 billion; +13.6%; 20th) showed high growth rates. Sales increased sharply for Kyowa Kirin’s renal anemia treatment Nesp and the anti-allergic drug Allelock. Sales of Ono were driven by the DPP-4 inhibitor Glactiv.

Growth Rate of Other Major Multinationals